Page 144 - CW E-Magazine (26-12-2023)

Pharmaceuticals Pharmaceuticals

NEW PROJECT
Ami Organics unveils new API manufacturing facility

in Ankleshwar

Ami Organics Ltd., a leading global
manufacturer of advance pharmaceuti-
designed to complement the existing cal intermediates (APIs) and speciality
three. The £45-mn (around $57-mn) in- chemicals, has announced the inau-
vestment was fi nanced by a combination guration of its manufacturing plant in
of Scottish Enterprise government grant, Ankleshwar, Gujarat.
bank loan, customer co-investment, and
internal accruals. The new manufacturing plant was
inaugurated in the presence of distin-
The expansion will enhance the site’s (L to R): Mr. Adrian Gillespie, Chief Executive of Scottish Enterprise; Mr. Herve Berdou, COO, guished customers, key stakeholders,
ability to deliver the full life cycle of ADC Piramal Pharma Solutions; Mr. Francois Houbart, Managing Director and Grangemouth Site and the leadership team of Ami Or- “Thes inauguration marks a signifi - turing in India,” said Mr. Naresh Patel,
development and manufacturing, includ- Head, Piramal Pharma Solutions; Ms. Nandini Piramal, Chairperson, Piramal Pharma Ltd; ganics. The Ankleshwar site, extend- cant leap forward for our Ankleshwar Executive Chairman & Managing
ing ADCelerate, the company’s branded Mr. Peter DeYoung, CEO, Piramal Pharma Solutions. ing over 10,375-sq.m., is undergoing facility. Achieving near completion Director, Ami Organics.
solution for the rapid early-stage deve- activities, along with new quality control Mr. Peter DeYoung, CEO, Piramal a signifi cant brownfi eld expansion to within a year since the groundwork
lopment of ADC drugs. This integrated laboratories, warehousing, offi ce space, Pharma Solutions, stated, “The global support the company’s burgeoning commenced, refl ects our team’s dedi- The new facility, which replaces the
offering combines the development of and supporting utilities. ADC market is growing strongly and so pharmaceutical intermediates business. cation and expertise. The new plant is previous facility, has been constructed
the monoclonal antibody (mAb), linker/ is the pipeline at Grangemouth, neces- The commencement of production is testimony to the state-of-the-art tech- with advanced technology and has
payload, conjugation, and sterile fi ll/ The building, which utilised modu- sitating additional capacity to meet cus- subject to receipt of necessary regula- nology we are bringing to advanced acquired all necessary environmental
fi nish into a single integrated programme lar construction technology to expe- tomer demand. This expansion allows tory approvals. pharmaceutical intermediate manufac- clearances.
across four global Piramal sites, includ- dite its completion, has been designed us to cater to further growth and take on NEW APPOINTMENTS
ing Grangemouth. The approach simpli- to accommodate further expansion. future projects. We see the market gra-
fi es development and manufacturing, “Potential future enhancements may vitating towards large and commercial Sigachi appoints Jerry White and Anu Aga as advisors
speeding the process to new compounds. include a new sterile fi ll/fi nish suite scale manufacturing, which the new faci-
dedicated to ADCs and two additional lity is well equipped to address. We for MENA region
The site expansion also includes a large-scale manufacturing suites capa- have now doubled our ADC production
dedicated customer experience centre ble of handling increased batch sizes,” capacity, strengthening our ability to Hyderabad-based pharma excipient through the Survivor Corps and shares from 1996 to 2004. Commenting on
for clients who are visiting the site dur- the company informed in a press note. service customers throughout the entire manufacturer, Sigachi Industries Ltd., in the Nobel Peace Prize with the Inter- these appointments, Mr. Amit Raj Sinha,
ing development and/or manufacturing Commenting on the development, drug lifecycle.” has announced the appointment of national Campaign to Ban Landmines. CEO, Sigachi, said the combined exper-
Mr. Jerry White and Ms. Anu Aga as tise of the advisors will strengthen the
Sun Pharma, Lupin recall drugs in US market: USFDA advisors for the Middle East and North Ms. Aga, a distinguished business company’s strategic initiatives and pro-
Africa (MENA) region. leader and philanthropist, is renowned for pel Sigachi to new heights. As advisors,
Leading drugmakers Sun Pharma due to “failed impurities/degradation pur-based facility. As per the USFDA, her contributions to corporate governance they will provide strategic guidance to
and Lupin are recalling products in the specifi cations”, the USFDA stated. the company is recalling the affected Sigachi MENA FZCO, a wholly- and sustainable business practices. She Sigachi’s mission to deliver high-quality
US market over manufacturing issues, The company commenced the voluntary lot due to “failed dissolution specifi - owned subsidiary of Sigachi Industries, led Thermax, an energy and environment solutions that meet the evolving needs of
as per the USFDA. nationwide Class II recall on December 4, cations”. The company initiated the had recently announced a joint venture engineering business, as its chairperson the MENA market.
this year. Class II nationwide (US) voluntary with Saudi National Projects Investment PROJECT MILESTONE
Sun Pharma is recalling 96,192 bot- recall on November 22. Ltd. (SNP), an investment advisory fund to
tles of Liothyronine sodium tablets in Lupin is recalling an unspecifi ed incorporate Sigachi Arabia. The company Atlas Life Sciences commences com-
the US used to treat an underactive thy- number of penicillamine tablets in the As per the USFDA, a Class II re- said the latest appointments sets “the stra-
roid, according to the health regulator. US. The medication is used to treat call is initiated in a situation in which tegic steps forward” to cater to the MENA mercial production at its new plant
Princeton-based Sun Pharmaceutical rheumatoid arthritis and Wilson’s dis- the use of, or exposure to, a product markets. Mr. White brings a wealth of
Industries Inc., a unit of the company, ease. Baltimore-based Lupin Pharma- may cause temporary or medically re- experience, having held key positions in Asahi Songwon Colors Ltd.’s wholly- mercial production of pharma inter-
is recalling the affected lot produced ceuticals Inc., a unit of the company, versible adverse health consequences various global organisations. He serves owned subsidiary, Atlas Life Sciences mediates at its new plant at Chhatral,
at the drugmaker’s Dadra-based faci- is recalling the affected lot that was or where the probability of serious ad- as Executive Director of the United Reli- (India) Pvt. Ltd., has announced that Dist: Gandhinagar, Gujarat on December
lity. The company is recalling the lot produced at the drugmaker’s Nag- verse health consequences is remote. gions Initiative, empowers war survivors it has successfully commenced com- 9, 2023.

144 Chemical Weekly December 26, 2023 Chemical Weekly December 26, 2023 145

Contents Index to Advertisers Index to Products Advertised